|Bid||0.00 x 800|
|Ask||0.00 x 1800|
|Day's Range||53.51 - 54.49|
|52 Week Range||49.96 - 70.05|
|PE Ratio (TTM)||95.63|
|Earnings Date||Jul 26, 2018|
|Forward Dividend & Yield||1.60 (2.92%)|
|1y Target Est||57.32|
Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer.
Below is a list of names for those charts we believe are showing technical characteristics of either bullish or bearish reversal patterns that occurred over the past week. Bullish reversals imply institutional accumulation and the potential for higher prices.
Big Pharma is struggling to keep up with the rest of the market this year as tepid revenue, growth, the expiration of key patents, and the likelihood of the government imposing tighter cost controls hold back its performance prospects. Earlier this month, while the broader S&P 500 was yielding just 2%, the dividend yield on the big drug companies in the index was nearly a full percentage point higher at 2.9%.
Bristol-Myers Squibb Company today announced that the ELOQUENT-3 trial, an international Phase 2 study evaluating the addition of Empliciti to pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma , achieved its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for patients treated with EPd ...
Bristol-Myers Squibb Company announced today that the China National Drug Administration has approved Opdivo for the treatment of locally advanced or metastatic non-small cell lung cancer after prior platinum-based chemotherapy in adult patients without EGFR or ALK genomic tumor aberrations.
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty cents per share on the $.10 par value Common Stock of the corporation.
Bristol-Myers Squibb Company today confirmed that 31 abstracts demonstrating The Company’s immunoscience-research focus as well as how ORENCIA® therapy may impact diverse patient subgroups will be presented at the Annual European Congress of Rheumatology , June 13-16 in Amsterdam.
Bristol-Myers Squibb Company (NYSE:BMY) is currently trading at a trailing P/E of 94.7x, which is higher than the industry average of 23.7x. Although some investors may jump to the conclusionRead More...
Bristol-Myers Squibb Company will take part in Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018, in Rancho Palos Verdes, CA. Johanna Mercier, Head of U.S.
The Hutch leased more than 100,000 square feet of space in the facility, bringing the cancer research center's South Lake Union footprint to 1.44 million square feet.
Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.
Shares have been on a roller-coaster ride since the company presented updated study results for its latest drug and outlined its goals at an investor conference on Wednesday.
Bristol-Myers Squibb Company will announce results for the second quarter of 2018 on Thursday, July 26, 2018. During a conference call at 10:30 a.m. EDT on July 26, company executives will review financial information and will address inquiries from investors and analysts.
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
When it was last covered in mid-May, few biotech investors questioned the valuation and prospects for Nektar Therapeutics (NASDAQ:NKTR) as shares held the $80 level. Such a quick drop is typical for any stock that rose by more than four-fold in under a year, but in the case of Nektar, investors are misinterpreting the clinical results. Nektar Therapeutics’ nearly 42 percent drop on June 4 now implies a more than two-fold upside for investors.
Nektar (NKTR) and Bristol-Myers Squibb announce preliminary data from the ongoing PIVOT phase I/II study evaluating the combination of Nektar's NKTR-214 with Bristol-Myers Squibb's Opdivo.
The latest results from a collaboration testing Bristol-Myers Squibb’s cancer drug Opdivo with Nektar Therapeutics’ NKTR-214 didn’t exactly impress investors. Wall Street analysts described the phase 1/2 clinical trial data as “underwhelming” and “immature,” and Nektar (NKTR) shares plummeted 41.8 on Monday. Combination treatments that pair two cancer drugs in an effort to boost their effect are an important trend in cancer research right now.
Shares plummeted after investors and Wall Street analysts found Nektar's mid-stage trial results for its collaborative effort with Bristol-Myers Squibb Co. to combine Nektar's NKTR-214 top immune-oncology program with Bristol-Myers' Opdivo drug to be below expectations. Response rates for patients with melanoma and kidney cancer patients decreased, according to the study that was released to the American Society of Clinical Oncology (ASCO) over the weekend.
Nektar's market cap, which was over $15 billion by Friday's close, fell to $9 billion by Monday's close. The fall came after data released Saturday suggested patients diagnosed with melanoma aren't reacting to the company's experimental treatment as well as earlier samples did. Shares of biotech company Nektar Therapeutics NKTR lost nearly half their value Monday after the company gave a clinical trial update that fell well short of investor expectations.